# Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

> **NCT03944876** · PHASE3 · RECRUITING · sponsor: **Norwegian University of Science and Technology** · enrollment: 112 (estimated)

## Conditions studied

- Cluster Headache

## Interventions

- **DRUG:** Botulinum toxin type A
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03944876
- **Lead sponsor:** Norwegian University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944876, "Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03944876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*